| Literature DB >> 33992116 |
Roberto Ucero-Lozano1, José Antonio López-Pina2, Alba Ortiz-Pérez3, Rubén Cuesta-Barriuso4,5.
Abstract
BACKGROUND: Recurrent hemarthrosis that begin in childhood lead to progressive joint deterioration. Patients with haemophilia have chronic pain, functional disability and a reduced perception of health-related quality of life.Entities:
Keywords: Catastrophism; Haemophilia; Joint damage; Joint pain; Kinesiophobia; Quality of life
Mesh:
Year: 2021 PMID: 33992116 PMCID: PMC8126122 DOI: 10.1186/s12891-021-04319-0
Source DB: PubMed Journal: BMC Musculoskelet Disord ISSN: 1471-2474 Impact factor: 2.362
Sample demographics and clinical characteristics, presented as mean (standard deviation)
| Variables | Items | Mean (SD) |
|---|---|---|
| Age | Age (years) | 43.87 (10.10) |
| Intake pain medication | Days/week | 4.13 (2.99) |
| Joint health | Ankle joint health (range 0–40) | 20.53 (5.35) |
| Knee joint health (range 0–40) | 17.83 (7.17) | |
| Elbow joint health (range 0–40) | 15.65 (5.50) | |
| Joint health (range 0-124) | 55.83 (16.06) | |
| Catastrophism | Perceived catastrophism | 10.12 (8.65) |
| Kinesiophobia | Perceived kinesiophobia | 30.60 (7.24) |
| Quality of life | Physical functioning (range 10–30) | 33.37 (22.11) |
| Role-physical (range 4–8) | 73.13 (24.12) | |
| Body pain (range 2–12) | 46.12 (21.43) | |
| General health (range 5–25) | 30.12 (17.96) | |
| Vitality (range 4–24) | 66.81 (9.89) | |
| Social functioning (range 2–10) | 67.05 (25.01) | |
| Role-emotional (range 3–6) | 95.01 (13.93) | |
| Mental health (range 5–30) | 72.92 (10.36) | |
| Physical component score (range 0–40) | 30.51 (8.62) | |
| Mental component score (range 0–40) | 56.07 (5.71) | |
| Joint pain | Habitual joint pain (range 0–10) | 4.48 (1.64) |
| Maximum joint pain (range 0–10) | 7.95 (1.37) | |
| n (%) | ||
| Clinical variables | Type of haemophilia (A/B) | 69 / 14 (83.1 / 16.9) |
| Severity of haemophilia (moderate/severe) | 12 / 71 (14.5 / 85.5) | |
| Type of treatment (on demand/prophylactic) | 24 / 59 (28.9 / 71.1) | |
| Development of inhibitors (no/yes) | 70 / 13 (84.3 / 15.7) | |
| Drug use (no/yes) | 25 / 58 (30.1 / 69.9) |
Correlations between quality of life and joint pain, joint health, catastrophism, kinesiophobia, age and weekly drug intake
| Quality of life items | Habitual joint pain | Maximum joint pain | Knee health | Ankle health | Elbow health | All joint health | Catastrophism | Kinesiophobia | Age | Weekly drug intake |
|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning | − 0.383** | − 0.444** | − 0.022 | 0.033 | − 0.194 | − 0.067 | − 0.350** | − 0.333** | 0.001 | − 0.506** |
| Role-physical | − 0.721** | − 0.575** | − 0.123 | − 0.077 | − 0.123 | − 0.129 | − 0.748** | − 0.628** | 0.174 | − 0.570** |
| Body pain | − 0.635** | − 0.681** | − 0.103 | − 0.131 | − 0.185 | − 0.156 | − 0.658** | − 0.644** | 0.436** | − 0.528** |
| General health | − 0.494** | − 0.519** | − 0.017 | − 0.025 | − 0.170 | − 0.071 | − 0.491** | − 0.515** | 0.375** | − 0.437** |
| Vitality | − 0.374** | − 0.398** | − 0.113 | − 0.107 | − 0.211 | − 0.165 | − 0.417** | − 0.454** | 0.329** | − 0.447** |
| Social functioning | − 0.559** | − 0.477** | − 0.069 | − 0.116 | − 0.220* | − 0.149 | − 0.528** | − 0.503** | 0.371** | − 0.382** |
| Role-emotional | − 0.197 | − 0.096 | − 0.187 | − 0.189 | − 0.030 | − 0.174 | − 0.218* | − 0.185 | − 0.238* | − 0.236* |
| Mental health | − 0.313** | − 0.316** | − 0.192 | − 0.198 | − 0.276* | − 0.259* | − 0.498** | − 0.420** | 0.195 | − 0.391** |
| Physical component score | − 0.657** | − 0.671** | − 0.033 | − 0.008 | − 0.191 | − 0.082 | − 0.626** | − 0.602** | 0.306** | − 0.597** |
| Mental component score | − 0.160 | − 0.077 | − 0.176 | − 0.226* | − 0.158 | − 0.223* | − 0.252* | − 0.223* | 0.103 | − 0.144 |
*Significant difference (p < .05)
** Significant difference (p < .001)
Relationship between quality of life and inhibitor development, treatment type, haemophilia severity and the consumption of drugs for pain control
| Quality of life items | Inhibitors | Treatment type | Haemophilia severity | Drug intake | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F | MD | 95 %CI | F | MD | 95 %CI | F | MD | 95 %CI | F | MD | 95 %CI | |
| Physical functioning | 0.15ª | 17.22 * | -32.56 - -1.88 | 3.29 | -6.68 | -17.30–3.93 | 0.54 | 25.28 ** | 12.64–37.91 | 0.11 | 21.50 ** | 12.03–30.96 |
| Role-physical | 1.18ª | 18.12 * | -35.41 - -0.84 | 2.66ª | -13.06 | -24.39 - -1.73 | 3.15 | 20.40 ** | 6.01–34.78 | 13.63ª | 27.80 ** | 20.32–35.37 |
| Body pain | 0.00 | 8.62 | -21.44–4.19 | 0.13 | -8.38 | -18.61–1.83 | 0.003 | 17.78 ** | 4.98–30.58 | 0.26 | 27.36 ** | 19.06–35.65 |
| General health | 2.75 | 2.33 | -13.18–8.51 | 1.27 | -4.28 | -12.94–4.36 | 2.32 | 16.81 ** | 6.21–27.40 | 0.72 | 15.85 ** | 7.99–23.71 |
| Vitality | 0.70 | 2.59 | -8.55–3.35 | 5.01 | 0.49 | -4.30–5.28 | 1.39 | 7.62 * | 1.68–13.57 | 4.17ª | 10.00 ** | 6.63–13.38 |
| Social functioning | 0.47 | 8.63 | -23.63–6.37 | 0.13 | -1.22 | -5.66–6.64 | 0.35 | 16.79 * | 1.61–31.98 | 0.76 | 20.88 ** | 9.82–31.93 |
| Role-emotional | 0.35 | -0.71 | -7.71–9.14 | 0.17 | -1.15 | -13.34–10.90 | 6.17ª | 5.83 ** | 2.30–9.36 | 14.56ª | 7.13 ** | 2.86–11.40 |
| Mental health | 0.09 | 1.08 | -7.34–5.17 | 0.86 | -0.82 | -7.90–5.59 | 6.80ª | 7.50 ** | 3.84–11.16 | 16.08ª | 9.45 ** | 6.16–12.74 |
| Physical component score | 0.31ª | 6.20 * | -12.70–0.28 | 0.51 | -3.83 | -5.84–4.19 | 0.11 | 9.72 ** | 4.78–14.66 | 4.39ª | 10.60 ** | 7.63–13.58 |
| Mental component score | 0.21 | -1.40 | -2.03–4.84 | 1.05 | 1.23 | -7.92–0.25 | 2.40 | 1.20 | -2.36–4.76 | 1.44 | 2.27 | -0.41–4.96 |
ª Mann-Whitney U test; MD: mean difference; 95 % CI: 95 % confidence interval
*Significant difference (p < .05)
** Significant difference (p < .01)
Effect of inhibitor development, treatment type, haemophilia severity and drugs use on the variance
| Quality of life items | Inhibitors | Treatment type | Haemophilia severity | Drug intake | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| t | df | r | t | df | r | t | df | r | t | df | r | |
| Physical functioning | 2.67 | 81 | 0.28 | -1.25 | 81 | 0.13 | 3.98 | 81 | 0.40 b | 4.52 | 81 | 0.44 b |
| Role-physical | 2.57 | 81 | 0.27 | -2.29 | 81 | 0.24 | 2.82 | 81 | 0.29 | 7.39 | 80.65 | 0.63 ª |
| Body pain | 1.33 | 81 | 0.14 | -1.63 | 81 | 0.17 | 2.76 | 81 | 0.29 | 6.56 | 81 | 0.58 ª |
| General health | 0.42 | 81 | 0.04 | − 0.98 | 81 | 0.10 | 3.15 | 81 | 0.33 | 4.01 | 81 | 0.40 b |
| Vitality | 0.86 | 81 | 0.09 | 0.16 | 29.23 | 0.03 | 2.55 | 81 | 0.27 | 5.90 | 75.94 | 0.56 ª |
| Social functioning | 1.14 | 81 | 0.12 | − 0.20 | 81 | 0.02 | 2.20 | 81 | 0.23 | 3.75 | 81 | 0.38 b |
| Role-emotional | − 0.16 | 81 | 0.01 | − 0.34 | 81 | 0.03 | 3.29 | 70.0 | 0.36 b | 3.34 | 57.0 | 0.40 b |
| Mental health | 0.34 | 81 | 0.03 | − 0.32 | 81 | 0.03 | 4.14 | 37.28 | 0.56 ª | 5.71 | 79.81 | 0.29 |
| Physical component score | 2.45 | 81 | 0.26 | -1.86 | 81 | 0.20 | 3.91 | 81 | 0.39 b | 7.13 | 64.08 | 0.66 ª |
| Mental component score | − 0.81 | 81 | 0.08 | 0.88 | 81 | 0.09 | 0.67 | 81 | 0.07 | 1.67 | 81 | 0.28 |
ª r > .50: the effect explains 25 % of the total variance
br > 0.30; the effect explains 9 % of the total variance